Kallikrein 6 as a Serum Prognostic Marker in Patients with Aneurysmal Subarachnoid Hemorrhage

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Martínez Morillo, Eduardo ^a   Diamandis, Anastasia ^b   Romaschin, Alexander D ^c   Diamandis, Eleftherios P ^a,b,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN 6;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN DAMAGE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DISABILITY SEVERITY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; SUBARACHNOID HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PEPTIDE HYDROLASES; PROGNOSIS; REFERENCE VALUES; S100 PROTEINS; SUBARACHNOID HEMORRHAGE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866661677     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045676     Document Type: Article

References (23)

1. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, et al. (2012) Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 43: 1711-1737.
2. Martin CO, Rymer MM, (2011) Hemorrhagic stroke: aneurysmal subarachnoid hemorrhage. Mo Med 108: 124-127.
3. van Gijn J, Kerr RS, Rinkel GJ, (2007) Subarachnoid haemorrhage. Lancet 369: 306-318.
4. Zacharia BE, Hickman ZL, Grobelny BT, DeRosa P, Kotchetkov I, et al. (2010) Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 21: 221-233.
5. Lovelock CE, Rinkel GJ, Rothwell PM, (2010) Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology 74: 1494-1501.
6. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, et al. (2009) Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 8: 635-642.
7. Ferro JM, Canhao P, Peralta R, (2008) Update on subarachnoid haemorrhage. J Neurol 255: 465-479.
8. Edlow JA, (2005) Diagnosis of subarachnoid hemorrhage. Neurocrit Care 2: 99-109.
9. Wang Y, Luo W, Reiser G, (2008) Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions. Cell Mol Life Sci 65: 237-252.
10. Shaw JL, Diamandis EP, (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53: 1423-1432.
11. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, et al. (2009) Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 29: 3269-3279.
12. Ashby EL, Kehoe PG, Love S, (2010) Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. Brain Res 1363: 1-10.
13. Menendez-Gonzalez M, Castro-Santos P, Suarez A, Calatayud MT, Perez-Pinera P, et al. (2008) Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease. J Alzheimers Dis 14: 59-67.
14. Menendez-Gonzalez M, Castro-Santos P, Calatayud MT, Perez-Pinera P, Ribacoba R, et al. (2008) Plasmatic level of neurosin predicts outcome of mild cognitive impairment. Int Arch Med 1: 11.
15. Scarisbrick IA, Sabharwal P, Cruz H, Larsen N, Vandell AG, et al. (2006) Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur J Neurosci 24: 1457-1469.
16. Terayama R, Bando Y, Takahashi T, Yoshida S, (2004) Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia 48: 91-101.
17. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, et al. (2002) Activity of a newly identified serine protease in CNS demyelination. Brain 125: 1283-1296.
18. Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, et al. (2002) Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41: 1165-1173.
19. Bando Y, Ito S, Nagai Y, Terayama R, Kishibe M, et al. (2006) Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci Lett 405: 175-180.
20. Martínez-Morillo E, Diamandis A, Diamandis EP, (2012) Reference intervals and biological variation for kallikrein 6: influence of age and renal failure. Clin Chem Lab Med 50: 931-934.
21. Vos PE, van Gils M, Beems T, Zimmerman C, Verbeek MM, (2006) Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol 13: 632-638.
22. Nylen K, Csajbok LZ, Ost M, Rashid A, Blennow K, et al. (2007) Serum glial fibrillary acidic protein is related to focal brain injury and outcome after aneurysmal subarachnoid hemorrhage. Stroke 38: 1489-1494.
23. Fraser CG (2001) Biological variation: from principles to practice. Washington: AACC Press.